Beyond Premarital Testing: A Smarter SRHR Approach to Thalassemia in Bangladesh
A routine blood test. A missed diagnosis. A lifelong consequence. In Bangladesh, thousands unknowingly carry thalassemia traits—yet the system continues to treat symptoms, not causes.
Thalassemia, a genetic blood disorder, is increasingly being recognized as a silent but significant Sexual and Reproductive Health and Rights (SRHR) issue. While carriers live healthy lives, the risk emerges when two carriers marry, potentially leading to severe thalassemia in children. As one expert insightfully notes, “The goal should not be to scare people, but to make them aware.”
For years, public messaging has emphasized premarital screening. However, in practice, this approach often creates stigma—especially for women. The term “carrier” is misunderstood, sometimes seen as a social liability. This undermines SRHR principles of dignity, informed choice, and non-discrimination.
A more practical solution lies in early, routine screening. Bangladesh already has wide access to CBC (Complete Blood Count) tests at upazila and জেলা levels. Low MCV and MCH levels—without iron deficiency—can indicate thalassemia trait. Yet, many patients are misdiagnosed with anemia and prescribed iron unnecessarily. As highlighted in the source, “People are given iron for years, while their actual condition remains undetected.”
From an SRHR lens, this is not just a clinical gap—it is a rights issue. Misdiagnosis affects reproductive decisions, maternal health, and family planning.
Globally, WHO estimates that around 5% of the world’s population carries a hemoglobin disorder gene, with South Asia being a high-burden region. In Bangladesh, studies suggest that 6–12% of people may be carriers, and thousands of children are born each year with severe forms like HbE-beta thalassemia.
The article proposes a shift: integrate screening into life-cycle health services—schools, university admissions, job check-ups, and especially antenatal care (ANC). Testing pregnant women first, followed by partners if needed, reduces social pressure while ensuring informed reproductive choices.
But screening alone is not enough.
Bangladesh lacks a national thalassemia registry, making it difficult to plan blood supply, treatment centers, or awareness campaigns. Patients dependent on transfusion face another barrier—safe blood access. Ideally, they require leukoreduced blood, which is still costly and limited.
Treatment options like bone marrow transplant remain inaccessible for most due to cost and infrastructure gaps. As a result, prevention through awareness and screening remains the most viable strategy.
The key message is clear:
“Being a carrier is not a disease.”
Reframing thalassemia within SRHR means promoting informed choice, reducing stigma, and embedding screening into routine healthcare—not isolating it within marriage.
A realistic national strategy—combining data systems, accessible diagnostics, counseling, and equitable treatment—can prevent suffering for future generations.